Taking peoplePhase 1
Tests PIT565 safety in adults with rheumatoid arthritis
Tests the safety of PIT565 at rising doses in adults with rheumatoid arthritis.
Key facts
- Who runs it
- Novartis Pharma AG
- Where
- Jena and Mainz, GermanySee the 2 sitesAlso in 6 other countries, 11 sites
- Trial code
- Registry title
- A phase Ib, open-label, ascending dose study to assess safety, tolerability and pharmacokinetics of PIT565 in participants with rheumatoid arthritis (RA)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 40 people, planned
- Started
- 1 Oct 2025
- Expected to end
- 15 May 2028
- Type of study
- Interventional
- Record updated
- 1 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with rheumatoid arthritis. It tests the safety of PIT565 at rising doses.
- Age
- 18 years or older
- Sex
- All sexes can join
Where in Germany
Also in 6 other countries, 11 sites
- Universitaetsklinikum Jena KöRJena, GermanyNo longer taking part
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests PIT565 safety in adults with rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 1 April 2026